AR and prostate carcinoma: Notably, combining L14‐8 with low dosages of AR antagonists, such as enzalutamide and darolutamide, significantly enhanced their anti‐tumor activity in the AR‐positive prostate cancer cell models (Figure S2, Supporting Information).